InsiderTrades.com logo
Pentagon contract could send this $2 AI stock soaring
From Behind the Markets   |   Ad
Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...
Get all the info here >>>
Ansbert Gadicke net worth and biography
  • Phone
  • Email
  • Website

Ansbert Gadicke Biography and Net Worth

Major Shareholder of Harpoon Therapeutics
Dr. Ansbert K. Gadicke M.D. serves as Independent Chairman of the Board of the Company. Dr. Gadicke joined our board of directors in May 2015. Dr. Gadicke co-founded MPM Capital’s venture investing activities in 1997 and has since served as a Managing Director. Prior to that, Dr. Gadicke led MPM Capital’s Advisory and Investment Banking business from 1992 to 1996 and was in Boston Consulting Group’s Health Care Group from 1989 to 1992. He is a member of the board of directors of Cullinan Oncology, LLC and ElevateBio, LLC and formerly served as a member of the board of directors of Radius Health, Inc. and Chiasma, Inc. Dr. Gadicke received his M.D. from J.W. Goethe University and has held research positions at the Whitehead Institute and Harvard University. Gadicke is qualified to serve as a member of our board of directors because of his extensive experience in the life sciences industry and in investment management.

What is Ansbert Gadicke's net worth?

The estimated net worth of Ansbert Gadicke is at least $5.71 million as of September 13th, 2021. Dr. Gadicke owns 248,170 shares of Harpoon Therapeutics stock worth more than $5,710,392 as of April 23rd. This net worth approximation does not reflect any other investments that Dr. Gadicke may own. Learn More about Ansbert Gadicke's net worth.

How do I contact Ansbert Gadicke?

The corporate mailing address for Dr. Gadicke and other Harpoon Therapeutics executives is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Harpoon Therapeutics can also be reached via phone at (650) 443-7400 and via email at [email protected]. Learn More on Ansbert Gadicke's contact information.

Has Ansbert Gadicke been buying or selling shares of Harpoon Therapeutics?

Ansbert Gadicke has not been actively trading shares of Harpoon Therapeutics during the last ninety days. Most recently, Ansbert Gadicke sold 1,849 shares of the business's stock in a transaction on Tuesday, June 1st. The shares were sold at an average price of $204.40, for a transaction totalling $377,935.60. Learn More on Ansbert Gadicke's trading history.

Who are Harpoon Therapeutics' active insiders?

Harpoon Therapeutics' insider roster includes Georgia Erbez (CFO), Ansbert Gadicke (Major Shareholder), and Holger Wesche (Insider). Learn More on Harpoon Therapeutics' active insiders.

Are insiders buying or selling shares of Harpoon Therapeutics?

In the last twelve months, Harpoon Therapeutics insiders bought shares 1 times. They purchased a total of 21,397,205 shares worth more than $492,135,715.00. The most recent insider tranaction occured on March, 11th when Major Shareholder Merck & Co., Inc. bought 21,397,205 shares worth more than $492,135,715.00. Insiders at Harpoon Therapeutics own 17.0% of the company. Learn More about insider trades at Harpoon Therapeutics.

Information on this page was last updated on 3/11/2024.

Ansbert Gadicke Insider Trading History at Harpoon Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/1/2021Sell1,849$204.40$377,935.60View SEC Filing Icon  
5/28/2021Sell1,388$211.20$293,145.60View SEC Filing Icon  
5/26/2021Sell319$200.40$63,927.60View SEC Filing Icon  
5/24/2021Sell500$201.20$100,600.00View SEC Filing Icon  
5/21/2021Sell1,090$202.10$220,289.00View SEC Filing Icon  
5/19/2021Sell1,783$203.90$363,553.70View SEC Filing Icon  
5/17/2021Sell466$200.70$93,526.20View SEC Filing Icon  
5/14/2021Sell690$200.40$138,276.00View SEC Filing Icon  
5/12/2021Sell2,968$205.30$609,330.40View SEC Filing Icon  
5/10/2021Sell1,713$218.00$373,434.00View SEC Filing Icon  
4/21/2021Sell897$189.70$170,160.90View SEC Filing Icon  
4/19/2021Sell1,005$193.00$193,965.00View SEC Filing Icon  
4/16/2021Sell584$198.60$115,982.40View SEC Filing Icon  
4/12/2021Sell2,062$210.20$433,432.40View SEC Filing Icon  
4/9/2021Sell1,030$236.70$243,801.00View SEC Filing Icon  
See Full Table

Ansbert Gadicke Buying and Selling Activity at Harpoon Therapeutics

This chart shows Ansbert Gadicke's buying and selling at Harpoon Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Harpoon Therapeutics Company Overview

Harpoon Therapeutics logo
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Read More

Today's Range

Now: $23.01
Low: $23.01
High: $23.01

50 Day Range

MA: $22.89
Low: $22.34
High: $23.01

2 Week Range

Now: $23.01
Low: $3.11
High: $23.21

Volume

N/A

Average Volume

1,516,200 shs

Market Capitalization

$389.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.11
Pentagon contract could send this $2 AI stock soaring
From Behind the Markets   |   Ad
Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...
Get all the info here >>>